Hero image

Skysong Innovations completes licensing agreement with ASU spinout OncoMyx Therapeutics

Immunotherapy company backed by $25 million in Series A financing is developing cancer treatments based on novel ASU technology

OncoMyx Therapeutics, an Arizona State University (ASU) spinout and privately-held oncolytic immunotherapy company founded on the myxoma virus (MYXV) platform, has finalized a licensing agreement with Skysong Innovations, ASU’s technology transfer organization.

Professor McFadden and his collaborators have developed a robust oncolytic virus technology, supported by preclinical and clinical research, that we believe could be a new pillar of cancer care

Steve Potts Co-founder and CEO of OncoMyx

Completing this licensing agreement is an important milestone for advancing this technology into new potentially life-saving treatments for cancer. It was great to work with the Skysong Innovations team on this licensing, because they understand not just the patent portfolio but what an inventor and entrepreneur needs to spin out a company and reach the next level.

Steve Potts Co-founder and CEO of OncoMyx

In June 2019, OncoMyx completed a $25 million Series A financing, one of the year’s largest venture investments in Arizona and the most money ever raised by an ASU spinout in its initial funding round. The company is using the proceeds to advance the development of its MYXV platform to the stage when it can begin human clinical trials.

OncoMyx has the potential to become the best-in-class oncolytic virus approach for treating a wide range of cancers, he company has tremendous IP, experienced leadership, and funding commensurate with the technology’s promise. They are a true shining star in the Arizona biotech startup scene.

Augie Cheng CEO of Skysong Innovations

Overall, companies launched to develop ASU’s intellectual property are boosting the state’s economy. To date, ASU researchers and other entrepreneurs have started more than 140 new companies, which together have attracted almost a billion dollars in outside investments. An independent economic impact analysis completed last year found that, from 2016-2019, Arizona’s economy gained a cumulative $575 million in gross state product, $52 million in state and local tax revenues, and 5,842 job-years (equivalent to one person having a job for one full year) as a result of Skysong Innovations’ venture development activities. The cumulative economic impact of these new companies is projected to reach $1.16 billion by the end of 2022.